RVNC News 28.28 Revance Therapeutics Inc. (RVNC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Revance Therapeutics Inc. (RVNC) 28.28 $RVNC

Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014

Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
GlobeNewswire - Mon Mar 31, 7:00PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000(R) and Russell 3000(R) Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.

Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
GlobeNewswire - Wed Mar 12, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:28PM CST
The beginning of the year swoon has decisively been put in the rearview mirror, with the broad-based S&P 500 launching itself to a new all-time high earlier this week on easing geopolitical fears. For skeptics like me, that's an opportunity to...

Revance to Add Angus C. Russell as Chairman to Its Board of Directors
GlobeNewswire - Wed Mar 05, 7:00AM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its Board of Directors, effective immediately.

Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston.

Revance Therapeutics Inc concludes USD110m IPO, including underwriters' over-allotment option
M2 - Wed Feb 12, 3:40AM CST
Biopharmaceutical company Revance Therapeutics Inc (NasdaqGS :RVNC) reported on Tuesday the completion of its initial public offering of 6,900,000 shares of common stock at a public offering price of USD16.00 per share.

Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Tue Feb 11, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock at the same price to cover over-allotments. Gross proceeds from the sale of the shares is approximately $110 million. The net proceeds from the sale of the shares, after deducting the underwriters' discount and other estimated offering expenses will be approximately $98.7 million.

IPO roundup: 5 companies start trading Thursday
AP - Thu Feb 06, 3:45PM CST
NEW YORK (AP) — Five companies began trading publicly on Thursday as the market for initial public offerings continued to go strong following a busy 2013. Three of the five are pharmaceutical companies.

Revance Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Feb 05, 8:15PM CST
Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "RVNC" on February 6, 2014. In addition, Revance has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on February 11, 2014, subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 36

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 156

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 68

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 50

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 10

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 165

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

Weave Partners with Affordable Care to Transform Patient Services

Updated Category News Views 213

Weave and Affordable Care: A Game-Changer for Dental Practices In today's competitive healthcare landscape, enhancing patient experience and operational efficiency is paramount. Recently, Affordable Care made a significant decision in choosing Weave as the go-to platform for patient communications, engagement, and payments. This strategic partnership aims to revolutionize...

Continue Reading
Exploring the Future Growth of Warehouse Management Systems

Updated Category News Views 207

Market Growth and Dynamics Overview The Warehouse Management System (WMS) market is witnessing remarkable growth, fueled by the surge in e-commerce and technology advancements. According to recent reports, this sector was valued at USD 3.50 billion in 2023, with expectations to reach USD 13.53 billion by 2032. This rapid ascent represents a compound annual growth rate...

Continue Reading
ArcSpan Technologies Partners with Major Publishers for Growth

Updated Category News Views 169

ArcSpan Technologies Partners with Leading Publishers ArcSpan Technologies, a recognized leader in AI-powered audience monetization solutions for global publishers, is thrilled to announce new partnerships with prominent publishers like A360, Sundial Media Group, USNews, and MediaCorp. These influential entities have chosen to implement ArcSpan's Audience Monetization...

Continue Reading
AI Revolutionizes Home Care: Balance of Promise and Peril

Updated Category News Views 20

AI in Home Care: Promise Meets Peril Ever wonder how technology's race to the future impacts the dustier corners of our lives? Well, AI is hitting home care in a big way, or so the National Council on Aging (NCOA) claims in their latest series, A New Era of Care. But before you start imagining a Jetsons-style home nurse, let's break down what's happening and why folks are...

Continue Reading
Whitestone Development and Empower CDC Innovate with Generators

Updated Category News Views 352

In a bold move shaking up the Houston real estate scene, Whitestone Development, Inc. has teamed up with Empower Community Development Corporation to roll out a pioneering residential community called Berry Square. This isn't just another cookie-cutter neighborhood; it's the first of its kind to throw a whole-home generator into every single house—a major nod towards...

Continue Reading